Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study.
Saved in:
| Title: | Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study. |
|---|---|
| Authors: | Nicolay JP; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/ University of Heidelberg, Mannheim, Germany.; Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany.; Section of Clinical and Experimental Dermatology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Melchers S; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/ University of Heidelberg, Mannheim, Germany.; Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany.; Section of Clinical and Experimental Dermatology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Albrecht JD; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/ University of Heidelberg, Mannheim, Germany.; Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany.; Section of Clinical and Experimental Dermatology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Assaf C; Department of Dermatology and Venereology, Helios Klinikum Krefeld, Krefeld, Germany.; Institute for Molecular Medicine, Medical School Hamburg, Hamburg, Germany., Dippel E; Department of Dermatology, Ludwigshafen Medical Center, Ludwigshafen, Germany., Stadler R; University Clinic for Dermatology, Johannes Wesling Medical Center, Minden, Germany., Wehkamp U; Department of Dermatology, Campus Kiel, University Hospital Schleswig-Holstein, Kiel, Germany., Wobser M; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany., Zhao J; Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany., Burghaus I; Clinical Study Coordination Center, University of Heidelberg, Heidelberg, Germany., Schneider S; Institute for Clinical Chemistry, University Medical Center Mannheim, Mannheim, Germany., Gülow K; Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious diseases, University Hospital Regensburg, Regensburg, Germany., Goerdt S; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/ University of Heidelberg, Mannheim, Germany., Schürch CM; Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany., Utikal JS; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/ University of Heidelberg, Mannheim, Germany.; Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany.; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany., Krammer PH; Department of Immunogenetics D030, German Cancer Research Center, Heidelberg, Germany. |
| Source: | Blood [Blood] 2023 Aug 31; Vol. 142 (9), pp. 794-805. |
| Publication Type: | Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
